



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0147.00004

In Re: Application Of: William Walker, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/590,680	8-25-06	Unknown	48924	Unknown	Unknown

Title: MATERIALS AND METHODS FOR TREATMENT OF ALLERGIC DISEASE

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0147.00004

In Application of: **William Walker, et al.**

Application No.
10/590,680

Filing Date
8-25-06

Examiner
Unknown

Customer No.
48924

Group Art Unit
Unknown

Confirmation No.
Unknown

Title: **MATERIALS AND METHODS FOR TREATMENT OF ALLERGIC DISEASE**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 11-1449 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

9-26-06

(Date)

Connie Herty

Signature of Person Mailing Correspondence

Connie Herty

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Kenneth I. Kohn, Reg. No. 30,955
KOHN & ASSOCIATES, PLLC
30500 Northwestern Highway, Suite 410
Farmington Hills, MI 48334
(248) 539-5050

Dated: September 26, 2006

CC:



MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO/SB/08-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number (Optional) 0147.00004		Application Number 10/590,680	
				Applicant William Walker, et al.			
				Filing Date 8-25-06		Group Art Unit Unknown	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/40478	17.09.98	PCT				

OTHER DOCUMENTS <i>(Including Author, Title, Date Pertinent Pages, Etc.)</i>	
	RNAi as a novel asthma therapeutic - Implications for IP development, RNAi & Treatment of Human Disease.
	Danahay, H. et al., "The <i>in vitro</i> and <i>in vivo</i> pharmacology of antisense oligonucleotides targeted to murine Stat6," <i>Inflamm. Res.</i> 49: 692-699 (2000).
	Hill, Sandra, et al., "Homologous Human and Murine Antisense Oligonucleotides Targeting Stat6," <i>Am. J. Respir. Cell Mol. Biol.</i> , Vol. 21, 728-737 (1999).
	New asthma drugs acting on gene expression: Progress in Molecular Pharmacology, <i>J. Cell. Mol. Med.</i> Vol. 7, No. 4, 475-486 (2003).
	Rippmann, Jorg F. et al., "Gene silencing with STAT6 specific siRNAs blocks eotaxin release in IL-4/TNFα stimulated human epithelial cells," <i>FEBS Letters</i> 579, 173-178 (2005).
	Arenz, Christoph, et al., "RNA interference: from an ancient mechanism to a state of the art therapeutic application?" <i>Naturwissenschaften</i> , 90:345-359 (2003).
	Henschel, Andreas, et al., "DEQOR: a web-based tool for the design and quality control of siRNAs," <i>Nucleic Acids Research</i> , Vol. 32, W113-W120 (2004).
	Ichim, Thomas E. et al., "RNA Interference: A Potent Tool for Gene-Specific Therapeutics," <i>American Journal of Transplantation</i> , 4:1227-1236 (2004).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE